| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dendritic Cells | 12 | 2020 | 59 | 3.130 |
Why?
|
| Alcohol Drinking | 4 | 2021 | 79 | 2.410 |
Why?
|
| Liver | 12 | 2021 | 184 | 2.290 |
Why?
|
| Liver Cirrhosis | 11 | 2024 | 64 | 2.130 |
Why?
|
| Liver Transplantation | 7 | 2021 | 80 | 1.740 |
Why?
|
| Hepatic Stellate Cells | 6 | 2020 | 9 | 1.380 |
Why?
|
| Alcoholism | 6 | 2021 | 85 | 1.370 |
Why?
|
| Liver Diseases, Alcoholic | 4 | 2021 | 46 | 1.170 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 33 | 1.050 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 121 | 0.970 |
Why?
|
| Ethanol | 3 | 2020 | 139 | 0.970 |
Why?
|
| End Stage Liver Disease | 3 | 2020 | 12 | 0.910 |
Why?
|
| Mice | 15 | 2021 | 1682 | 0.840 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 7 | 0.830 |
Why?
|
| Sex Factors | 2 | 2021 | 511 | 0.810 |
Why?
|
| Macrophages | 2 | 2021 | 137 | 0.800 |
Why?
|
| Hepatocytes | 2 | 2020 | 10 | 0.790 |
Why?
|
| Animals | 21 | 2021 | 4722 | 0.770 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2021 | 2 | 0.760 |
Why?
|
| Mice, Inbred C57BL | 9 | 2020 | 466 | 0.720 |
Why?
|
| Hepatitis, Autoimmune | 4 | 2024 | 10 | 0.720 |
Why?
|
| Chemical and Drug Induced Liver Injury | 3 | 2015 | 13 | 0.530 |
Why?
|
| Cytokines | 7 | 2021 | 351 | 0.520 |
Why?
|
| Homeostasis | 2 | 2014 | 86 | 0.470 |
Why?
|
| Bone Marrow | 1 | 2014 | 81 | 0.440 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2008 | 9 | 0.440 |
Why?
|
| Neutrophils | 1 | 2014 | 120 | 0.430 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 781 | 0.420 |
Why?
|
| Female | 20 | 2024 | 16980 | 0.420 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2012 | 1 | 0.400 |
Why?
|
| Immunity, Cellular | 3 | 2011 | 63 | 0.380 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2011 | 6 | 0.370 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 7 | 0.370 |
Why?
|
| Hypoxia | 2 | 2022 | 63 | 0.370 |
Why?
|
| Hepacivirus | 5 | 2021 | 76 | 0.360 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 19 | 0.330 |
Why?
|
| Mice, Transgenic | 6 | 2017 | 261 | 0.320 |
Why?
|
| Humans | 23 | 2024 | 30994 | 0.320 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 131 | 0.310 |
Why?
|
| Graft Rejection | 2 | 2020 | 74 | 0.300 |
Why?
|
| Spleen | 2 | 2012 | 55 | 0.300 |
Why?
|
| Male | 16 | 2021 | 16442 | 0.290 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 80 | 0.280 |
Why?
|
| Central Nervous System Depressants | 1 | 2006 | 24 | 0.270 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 95 | 0.270 |
Why?
|
| Liver Regeneration | 2 | 2020 | 23 | 0.270 |
Why?
|
| Liver Diseases | 2 | 2021 | 41 | 0.240 |
Why?
|
| Hepatitis C | 2 | 2021 | 67 | 0.240 |
Why?
|
| Adenine | 1 | 2003 | 3 | 0.230 |
Why?
|
| Organophosphonates | 1 | 2003 | 5 | 0.230 |
Why?
|
| Lamivudine | 1 | 2003 | 22 | 0.230 |
Why?
|
| Hepatitis B, Chronic | 1 | 2003 | 6 | 0.230 |
Why?
|
| Inflammation | 3 | 2017 | 362 | 0.230 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 86 | 0.230 |
Why?
|
| Models, Animal | 2 | 2020 | 130 | 0.220 |
Why?
|
| Risk Factors | 5 | 2020 | 2586 | 0.220 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2022 | 2 | 0.210 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 2 | 0.210 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 10 | 0.210 |
Why?
|
| Biomarkers | 3 | 2021 | 733 | 0.210 |
Why?
|
| Monocytes | 2 | 2021 | 115 | 0.200 |
Why?
|
| Antiviral Agents | 1 | 2003 | 135 | 0.200 |
Why?
|
| Disease Progression | 5 | 2021 | 829 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2014 | 184 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 20 | 0.190 |
Why?
|
| Adult | 8 | 2021 | 8929 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2024 | 3656 | 0.190 |
Why?
|
| Prejudice | 1 | 2021 | 41 | 0.190 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2020 | 1 | 0.180 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 20 | 0.180 |
Why?
|
| Middle Aged | 11 | 2021 | 10192 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 135 | 0.180 |
Why?
|
| Flow Cytometry | 3 | 2021 | 204 | 0.170 |
Why?
|
| Patient Selection | 1 | 2021 | 246 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 81 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 64 | 0.170 |
Why?
|
| Transcriptome | 1 | 2020 | 89 | 0.170 |
Why?
|
| Interferon-alpha | 1 | 2019 | 68 | 0.160 |
Why?
|
| Obesity | 1 | 2021 | 307 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 101 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 274 | 0.150 |
Why?
|
| Binge Drinking | 1 | 2017 | 10 | 0.150 |
Why?
|
| Cholesterol, Dietary | 1 | 2017 | 2 | 0.150 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2017 | 2 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2020 | 532 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2020 | 328 | 0.150 |
Why?
|
| Intestinal Absorption | 1 | 2017 | 42 | 0.150 |
Why?
|
| Quality of Life | 1 | 2022 | 697 | 0.140 |
Why?
|
| Cell Survival | 2 | 2014 | 164 | 0.140 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2014 | 3 | 0.140 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2016 | 6 | 0.130 |
Why?
|
| Interleukin-15 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Colon | 1 | 2017 | 163 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1133 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 4 | 2013 | 270 | 0.130 |
Why?
|
| Mice, Knockout | 2 | 2014 | 322 | 0.130 |
Why?
|
| Stem Cells | 1 | 2016 | 49 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 2016 | 31 | 0.130 |
Why?
|
| Apoptosis | 2 | 2014 | 260 | 0.130 |
Why?
|
| Adoptive Transfer | 2 | 2013 | 46 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2016 | 103 | 0.120 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2015 | 4 | 0.120 |
Why?
|
| CD11c Antigen | 1 | 2014 | 1 | 0.120 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 4 | 0.120 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2014 | 5 | 0.120 |
Why?
|
| Aged | 7 | 2021 | 10045 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 10 | 0.120 |
Why?
|
| Circadian Rhythm | 1 | 2017 | 294 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2014 | 30 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 36 | 0.110 |
Why?
|
| Young Adult | 4 | 2021 | 2063 | 0.110 |
Why?
|
| Hospitalization | 3 | 2021 | 336 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 118 | 0.110 |
Why?
|
| Thymus Gland | 1 | 2013 | 26 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 60 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 82 | 0.110 |
Why?
|
| Lipopolysaccharides | 3 | 2012 | 133 | 0.110 |
Why?
|
| Hepatitis | 1 | 2013 | 9 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 223 | 0.110 |
Why?
|
| Phenotype | 2 | 2012 | 379 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2013 | 91 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2015 | 685 | 0.110 |
Why?
|
| Cytokine Receptor Common beta Subunit | 1 | 2012 | 1 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 22 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 10 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 29 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2012 | 16 | 0.100 |
Why?
|
| Immune Tolerance | 2 | 2013 | 21 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 18 | 0.090 |
Why?
|
| Prognosis | 2 | 2016 | 918 | 0.090 |
Why?
|
| Liver Function Tests | 2 | 2021 | 26 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2012 | 152 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2020 | 204 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2008 | 35 | 0.090 |
Why?
|
| Registries | 2 | 2020 | 201 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2016 | 991 | 0.080 |
Why?
|
| Microspheres | 1 | 2008 | 40 | 0.080 |
Why?
|
| Time Factors | 2 | 2017 | 1672 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5189 | 0.070 |
Why?
|
| Transplantation, Isogeneic | 1 | 2006 | 2 | 0.070 |
Why?
|
| Poly I-C | 1 | 2006 | 6 | 0.070 |
Why?
|
| Endocytosis | 1 | 2006 | 17 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2006 | 101 | 0.070 |
Why?
|
| Immunity | 1 | 2006 | 26 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2021 | 86 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 217 | 0.060 |
Why?
|
| Adolescent | 2 | 2021 | 2401 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2015 | 497 | 0.060 |
Why?
|
| Recurrence | 2 | 2016 | 370 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 2042 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 46 | 0.060 |
Why?
|
| Viral Core Proteins | 1 | 2004 | 4 | 0.060 |
Why?
|
| Gene Products, pol | 1 | 2003 | 1 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2004 | 13 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2003 | 7 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2004 | 93 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2003 | 43 | 0.060 |
Why?
|
| DNA, Viral | 1 | 2003 | 97 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 271 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2004 | 134 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 246 | 0.050 |
Why?
|
| Selection Bias | 1 | 2021 | 9 | 0.050 |
Why?
|
| Mutation | 1 | 2003 | 409 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 2 | 0.050 |
Why?
|
| Propensity Score | 1 | 2021 | 36 | 0.050 |
Why?
|
| Europe | 1 | 2021 | 79 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 24 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 51 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 99 | 0.050 |
Why?
|
| Creatinine | 1 | 2020 | 45 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 58 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 155 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 97 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 89 | 0.040 |
Why?
|
| Viral Proteins | 2 | 2013 | 24 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 320 | 0.040 |
Why?
|
| Thrombomodulin | 1 | 2019 | 3 | 0.040 |
Why?
|
| Antigens, CD1 | 1 | 2019 | 6 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2019 | 27 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 409 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 29 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 117 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2019 | 59 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2019 | 111 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 89 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 507 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 346 | 0.040 |
Why?
|
| Animal Feed | 1 | 2017 | 6 | 0.040 |
Why?
|
| Rats | 1 | 2020 | 873 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 18 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 718 | 0.040 |
Why?
|
| Permeability | 1 | 2017 | 139 | 0.040 |
Why?
|
| Eating | 1 | 2017 | 55 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2017 | 101 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1210 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 98 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2017 | 232 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2004 | 149 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2375 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 37 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 35 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 43 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 2013 | 21 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2013 | 79 | 0.030 |
Why?
|
| Carbon Tetrachloride | 1 | 2013 | 1 | 0.030 |
Why?
|
| Propanols | 1 | 2013 | 1 | 0.030 |
Why?
|
| Thymidine Kinase | 1 | 2013 | 2 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 48 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2013 | 110 | 0.030 |
Why?
|
| Ganciclovir | 1 | 2013 | 28 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 31 | 0.030 |
Why?
|
| Fibrosis | 1 | 2013 | 39 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 81 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 2012 | 1 | 0.030 |
Why?
|
| Listeriosis | 1 | 2012 | 6 | 0.030 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2012 | 12 | 0.030 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 10 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2012 | 31 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2012 | 49 | 0.030 |
Why?
|
| Endotoxemia | 1 | 2012 | 30 | 0.030 |
Why?
|
| Cell Line | 1 | 2013 | 305 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2012 | 30 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 176 | 0.020 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2012 | 43 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 165 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 178 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1921 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 13 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2008 | 31 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2008 | 9 | 0.020 |
Why?
|
| CD40 Antigens | 1 | 2008 | 9 | 0.020 |
Why?
|
| Immunomagnetic Separation | 1 | 2008 | 4 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 47 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 57 | 0.020 |
Why?
|
| Plasmids | 1 | 2008 | 45 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 45 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3806 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 226 | 0.020 |
Why?
|
| Mitochondria, Liver | 1 | 2006 | 3 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2006 | 38 | 0.020 |
Why?
|
| Virus Replication | 1 | 2006 | 94 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2004 | 19 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 2004 | 10 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 36 | 0.010 |
Why?
|
| Buthionine Sulfoximine | 1 | 2004 | 1 | 0.010 |
Why?
|
| Fluoresceins | 1 | 2004 | 8 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 32 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 126 | 0.010 |
Why?
|